Michael Barbella, Managing Editor05.24.24
Paindrainer AB has been awarded a Euroean patent for its proprietary platform for 360° patient-centricity, chronic pain management, powered by an artificial neural network.
At its core, this patent outlines a personalized pain-management platform that leverages users’ own data and a neural network analysis to provide tailored recommendations. These recommendations are fully adaptive to each user, aiming to alleviate pain and enhance quality of life by adjusting behaviours or activities. The patent is also the basis for pursuing additional protection for other indications.
"The successful grant of our patent marks a significant milestone in our journey towards revolutionizing pain management. Our system exemplifies our commitment to leveraging cutting-edge technology with the potential to enhance staff efficiency in pain clinics through remote monitoring, while improving patient retention and adherence to treatment plans. The approval means that we effectively protect the company’s intangible assets," Paindrainer AB CEO Erik Frick said.
Paindrainer AB collaborates with Potter Clarkson LLP (law firm) for strategies and applications. The Paindrainer mobile application is the first evidence-based digital tool demonstrating improved quality of life for individuals living with chronic pain. The product is registered with the U.S. Food and Drug Administration as a Class I medical device. The solution is powered by leveraging advanced algorithms and is fully adaptive to each individual patient, featuring the unique proprietary 360-degree patient-centric approach. This approach provides guidance on how to achieve a personalized activity balance to reach an optimal functional level and alleviate pain.
“This is a significant patent in the field of pain management, which will bring much-needed relief to patients suffering from a wide range of conditions associated with chronic pain. In examining the patent application, the European Patent Office did not find anything even remotely similar to this technology, which underlines what a breakthrough it is and reinforces Paindrainer’s position at the forefront of pain management. We are pleased to have been able to support the company in protecting their innovation with this successful and important patent,” Potter Clarkson Partner Dave Clark stated.
Founded in 2018 by Prof. Carl Borrebaeck, Dr. Maria Rosén Klement, and Göran Barkfors, Paindrainer AB develops digital platforms and applications contributing to health and well-being. Paindrainer is the first evidence-based AI powered digital tool that coaches users in managing their pain and provides guidance on ways to reach a personalized activity balance to alleviate pain. The tool is MDR compliant and CE Marked.
At its core, this patent outlines a personalized pain-management platform that leverages users’ own data and a neural network analysis to provide tailored recommendations. These recommendations are fully adaptive to each user, aiming to alleviate pain and enhance quality of life by adjusting behaviours or activities. The patent is also the basis for pursuing additional protection for other indications.
"The successful grant of our patent marks a significant milestone in our journey towards revolutionizing pain management. Our system exemplifies our commitment to leveraging cutting-edge technology with the potential to enhance staff efficiency in pain clinics through remote monitoring, while improving patient retention and adherence to treatment plans. The approval means that we effectively protect the company’s intangible assets," Paindrainer AB CEO Erik Frick said.
Paindrainer AB collaborates with Potter Clarkson LLP (law firm) for strategies and applications. The Paindrainer mobile application is the first evidence-based digital tool demonstrating improved quality of life for individuals living with chronic pain. The product is registered with the U.S. Food and Drug Administration as a Class I medical device. The solution is powered by leveraging advanced algorithms and is fully adaptive to each individual patient, featuring the unique proprietary 360-degree patient-centric approach. This approach provides guidance on how to achieve a personalized activity balance to reach an optimal functional level and alleviate pain.
“This is a significant patent in the field of pain management, which will bring much-needed relief to patients suffering from a wide range of conditions associated with chronic pain. In examining the patent application, the European Patent Office did not find anything even remotely similar to this technology, which underlines what a breakthrough it is and reinforces Paindrainer’s position at the forefront of pain management. We are pleased to have been able to support the company in protecting their innovation with this successful and important patent,” Potter Clarkson Partner Dave Clark stated.
Founded in 2018 by Prof. Carl Borrebaeck, Dr. Maria Rosén Klement, and Göran Barkfors, Paindrainer AB develops digital platforms and applications contributing to health and well-being. Paindrainer is the first evidence-based AI powered digital tool that coaches users in managing their pain and provides guidance on ways to reach a personalized activity balance to alleviate pain. The tool is MDR compliant and CE Marked.